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Abstract: Delayed-type hypersensitivity reactions (DTHRs) after
subcutaneous application of unfractionated heparins or low-
molecular-weight heparins are not uncommon. Standard allergo-
logical testing usually includes intracutaneous skin tests and patch
testing of different heparins, heparinoids, and thrombin inhibitors
followed by subcutaneous and/or intravenous challenge with skin
testYnegative drugs. We present data from a single-center case series
of 15 patients with DTHR after low-molecular-weight heparin ad-
ministration. Intracutaneous testing that can be considered as gold
standard identiﬁed the suspicious elicitor in 11 (73.4%) of 15 of the
patients. Patch testing was positive in 5 (33.4%) of 15 of the patients
and was only positive in patients who were also reacting in the
intradermal testing. Intravenous challenge with heparin sodium was
performed in 10 of 15 patients and was well tolerated in all cases,
despite prior positive intracutaneous tests with the same substance.
Intracutaneous documentation of DTHR was not an adequate pre-
dictor of intravenous challenge.
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surgery, thrombosis
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Heparins have been used for the treatment and prophylaxisof thromboembolic diseases for about 6 decades.1 All
heparins are sulfated mucopolysaccharides with a highly neg-
ative charge. Unfractionated heparins (UFHs), such as heparin
calcium and heparin sodium with a molecular weight of 12 to
20 kd, have to be distinguished from low-molecular-weight
heparins (LMWHs) such as enoxaparin, dalteparin, nadro-
parin, and certoparin with a molecular weight of 4 to 6 kd.
Unfractionated heparins are extracted from porcine intestinal
mucosa or bovine lung. Low-molecular-weight heparins are
manufactured by fractionation of UFH.2 In addition to hep-
arins, further anticoagulatory drugs are available: semisyn-
thetic heparinoids such as danaparoid sodium, synthetic
pentasaccharides such as fondaparinux natrium, and direct
thrombin inhibitors, that is, the hirudins lepirudin and de-
sirudin or synthetic thrombin inhibitors such as argatroban
and bivalirudin.
Hypersensitivity reactions against heparins, heparinoids,
and hirudins are well known and can induce different hyper-
sensitivity reactions according to the classiﬁcation by Coombs
and Gell (Table 1).3 Immediate-type reactions (type I reac-
tions), that is, generalized urticaria, angioedema, broncho-
spasm, and severe anaphylaxis are rare and have been reported
for UFH, LMWH, and lepirudin. A severe adverse event of
heparins is heparin-induced thrombocytopenia (HIT) type II, a
classic type II reaction induced by polyclonal antibodies,
usually against the heparinYplatelet factor 4 complex.4 Cu-
taneous manifestations of HIT type II may include erythemas
and skin and mucosal necrosis. The Arthus reaction represents
a type III reaction resulting from antigen-antibody complexes
and is characterized by inﬂammation, erythematous indura-
tion, and edema at the injection site, which can result in sub-
sequent hemorrhage and necrosis.5 The most common type of
heparin hypersensitivity is the delayed-type hypersensitivity
reaction (DTHR), a type IV allergic reaction characterized by
itchy eczema and plaques at the injection sites (Fig. 1). His-
tological investigation of skin biopsies from DTHR lesions
usually shows a mixed perivascular inﬁltrate with many
eosinophils and dermal edema (Fig. 2). These reactions have
ﬁrst been described by Plancherel6 in 1953 and become ev-
ident in nonsensitized individuals within 10 to more than
20 days after treatment initiation. Once sensitized, patients
react commonly within 2 to 3 days after reexposure. Until
now, the pathomechanism of these DTHR is not completely
understood. The heparin molecule itself does not seem to be
immunogenic. It is assumed that binding of the molecule to
hitherto unknown cutaneous or subcutaneous proteins trans-
fers the hapten heparin into a full antigen.2
Risk factors for the development of DTHR to heparins
are female sex, older age, pregnancy, and probably obesity and
prolonged exposure to heparins.5,7 It is still controversially
discussed whether the molecular weight of the different hep-
arins also inﬂuences the risk for development of DTHR.7Y9
As the clinical picture does not necessarily allow the
classiﬁcation of the underlying allergologic mechanism, al-
lergy testing includes different procedures: skin prick testing,
intracutaneous and patch testing of UFH and LMWH,
heparinoids, hirudins, and further synthetic thrombin inhibi-
tors, followed by subcutaneous or intravenous challenge. In
cases of DTHR, an alternative drug for subcutaneous appli-
cation can easily be identiﬁed using these tests. As several
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heparins, hirudins, and synthetic thrombin inhibitors are con-
traindicated during pregnancy, the choice for an alternative
drug in pregnant women is more difﬁcult. This is also true for
patients undergoing cardiac surgery, in particular, with ex-
tracorporeal circulation. In that situation, there is sometimes
not enough time to carry out the complete allergologic test
procedure if surgery is required without delay. In addition, the
alternative substances may have relevant drawbacks in con-
junction with extracorporeal circulation. Furthermore, it is
still unclear if patients with DTHR have an increased risk to
develop systemic complications or HIT type II.
To deﬁne possible cross reactions between subcuta-
neously and intravenously applied heparin, we studied 15
patients with a history of DTHR after heparin application.
MATERIALS AND METHODS
Patients
Fifteen patients (3 male, 12 female) with a median age of
49 years (range, 26Y72 years) suspected for heparin allergy
were examined and tested during a period of 18 months from
January 2007 to June 2008 at the allergologic outpatient unit
of the Department of Dermatology. Fourteen patients had a
TABLE 1. Overview of Different Anticoagulatory Drugs, Their Way of Application and Testing, Cross-Reactivity With Other










IV or SC Undiluted LMWH, heparin sodium Skin necrosis, urticaria, bronchospasm,





IV or SC Undiluted LMWH, heparin calcium Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Dalteparin LMWH SC Undiluted UFH, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Nadroparin LMWH SC Undiluted UFM, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Enoxaparin LMWH SC Undiluted UFM, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Repivarin LMWH SC Undiluted UFM, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Tinzaparin LMWH SC Undiluted UFM, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Certoparin LMWH SC Undiluted UFM, other LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, HIT type II, DTHR
Pentosan
polysulfate
Semisynthetic heparinoid SC Undiluted UFM, LMWH Skin necrosis, urticaria, bronchospasm,
anaphylaxis, fever, chills,
HIT type II, DTHR
Danaparoid Semisynthetic heparinoid IV or SC Undiluted LMWH Rash, maculopapular exanthemas,
pustulosis, pruritus, DTHR
Lepirudin Recombinant hirudin IV Undiluted Bivalirudin Anaphylactic and anaphylactoid reactions
(including fatal outcome), DTHR,
exanthemas, fever, chills
Fondaparinux Synthetic pentasaccharide SC (IV possible) Undiluted UFM, LMWH Urticaria, edema, anaphylaxis, rash, DTHR
Bivalirudin Synthetic thrombin inhibitor IV Undiluted Not reported Urticaria, anaphylaxis
(including fatal outcome)
Argatroban Synthetic thrombin inhibitor IV Undiluted Not reported Rash, urticaria, bullous dermatitis,edema
IV indicates intravenous; SC, subcutaneous.
FIGURE 1. Erythematous and scaly plaques with inﬂammatory inﬁltration as a sign of DTHR in 2 patients after injection of
nadroparin (A) or enoxaparin (B) into the skin of the abdominal wall.
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history of DTHR after administration of LMWH, 1 patient
reported the development of eczema after local application of a
heparin ointment. None of the patients had a history of HIT
type II. Four female patients had developed itchy plaques on
the injection sites of LMWH during pregnancy, and 6 patients
required urgent cardiac surgery with extracorporeal circulation
for treatment of coronary heart disease or cardiac valve
dysfunction.
The patient characteristics are shown in Table 2.
Skin Allergy Tests
Intracutaneous tests on the inner forearm of the patients
included heparin calcium, heparin sodium, dalteparin, nadro-
parin, enoxaparin, repivarin, tinzaparin, certoparin, pentosan
polysulfate, danaparoid, lepirudin, and fondaparinux sodium
and were performed using 0.05 mL of the original undiluted
drug. The test results were read 20 minutes and 24, 48, 72, and
96 hours after injection (Fig. 3). Ten of 15 patients were tested
with the whole series of mentioned heparins.
Patch tests with the same drugs were carried out on the
back. Patch testing was performed by using the undiluted drug
on Curatest chambers (Lohmann und Rauscher, Vienna,
Austria). Application was performed for 24 hours. In addition,
patch testing included the German standard test series (Hermal,
Reinbek, Germany) as well as the preservatives chlorocresol,
benzalkonium chloride, and thiomersal that are sometimes
used in different brands of heparins. Readings were taken on
days 2, 3, and 4 according to International Contact Dermatitis
Research Group guidelines.
Subcutaneous Challenge
A subcutaneous challenge was performed by injection of
a therapeutic dose of selected skin testYnegative drugs into the
abdominal skin. Results were obtained after 20 minutes and
24, 48, 72, and 96 hours after drug administration, in some
cases, even after 96 and 120 hours.
FIGURE 2. Focally spongiotic epidermis with mixed in-depth
perivascular inﬁltrate with many eosinophils and dermal edema
(hematoxylin and eosin [HE] staining, magniﬁcation 400).
TABLE 2. Characteristics of Patients
Patient Sex Age, y Elicitor Special Features
1 Female 66 Tinzaparin, certoparin, danaparoid Heart surgery
2 Female 72 Certoparin Heart surgery
3 Male 47 Nadroparin Heart surgery
4 Female 49 Enoxaparin V
5 Female 55 Enoxaparin, nadroparin V
6 Female 71 Enoxaparin Heart surgery
7 Male 65 Heparin ointment Heart surgery
8 Female 39 Enoxaparin Pregnancy
9 Female 54 Enoxaparin V
10 Female 36 Enoxaparin Pregnancy
11 Male 46 Enoxaparin V
12 Female 59 LMWH Heart surgery
13 Female 46 Enoxaparin, certoparin V
14 Female 36 Enoxaparin, dalteparin Pregnancy
15 Female 26 Dalteparin, nadroparin Pregnancy
FIGURE 3. Results of intracutaneous heparin testing, 96 hours
after injection of UFH and LMWH into the volar aspect of the
forearm. The injection of heparin calcium, dalteparin, and
heparin sodium led to inﬁltrated lesions with blisters.
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Intravenous Challenge
Intravenous challenge was performed in 10 of 15
patients reactive to UFH in skin testing and in patients re-
quiring cardiac surgery immediately or with known cardio-
vascular disease (patients 1, 2, 3, 4, 5, 6, 7, 9, 12, and 13). For
intravenous challenge, the patients were hospitalized. We
applied heparin sodium as a bolus in a dose of 2500 IU on day
1, 5000 IU as a bolus followed by 7500 IU for 6 hours on day
2, with a follow-up period of 24 hours on an inpatient basis,
and a further 24 and 48 hours on an outpatient basis.
RESULTS
In 11 (73.4%) of 15 patients, the suspected LMWHcould
be proven as elicitor by intracutaneous testing (Fig. 3). In 1 case
(patient 3), no LMWHs were tested as heart surgery had to be
performed without delay. In a female patient (patient 15) with
reported DTHR after application of dalteparin and nadroparin
during pregnancy, intracutaneous testing performed after birth
of the child was negative. In the case of the patient with a
history of eczema after application of a heparin ointment
(patient 7), intracutaneous testing showed no pathological
reaction. Complete test results of intracutaneous testing are
shown in Table 3.
Patch testing of suspected drugs was positive in 5
(33.4%) of 15 of the patients. In cases with positive patch tests,
patch test results only proved the results of intracutaneous
testing. There was no case with a positive result in patch
testing without any positive intracutaneous test. Patch testing
of the preservatives chlorocresol, benzalkonium chloride, and
thiomersal was negative in all patients.
Subcutaneous challenge was performed with different
drugs according to the medical history of the individual patient.
In 6 patients with negative standard testing (intracutaneous and
patch testing), conﬁrmation of an allergic response to heparin
was found after subcutaneous challenge. Application of
danaparoid and lepirudin was followed by DTHR in 2 patients
with negative skin testing and a history of DTHR after
enoxaparin administration. Fondaparinux sodium was given
subcutaneously in 14 of 15 patients and was well tolerated
without development of DTHR in all cases.
Intravenous provocation with heparin sodium was
performed as previously described in 10 of 15 patients and
tolerated well in all cases.
DISCUSSION
Adverse reactions to heparin are relatively common. In
most cases, patients developDTHR against LMWH. If patients
receive LMWH as thromboembolic prophylaxis after an
operation, as a treatment of deep venous thrombosis or as a
prophylaxis because of increased risk of thromboembolic
diseases, there are many alternatives that should be taken into
consideration. Heparinoids such as pentosan polysulfate or
danaparoid or recombinant hirudins such as lepirudin are
recommended as drugs of ﬁrst choice because the replacement
of 1 LMWHwith another LMWH is not appropriate because of
cross-reactivity between all LWMHs.7
In pregnant women, the choice of treatment alternatives
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pregnancy. Although danaparoid seems to be a good alterna-
tive drug for pregnant women at risk of thromboembolic
complications, there are several reports indicating that patients
experiencing a DTHR against LMWH in the past also devel-
oped DTHR after changing to danaparoid administration.10,11
We could conﬁrm this phenomenon in our collective: 2 of 4
female patients who developed DTHR during pregnancy came
to us with DTHR against danaparoid that had been given after
development of DTHR after LMWH administration. Another
pregnant female patient was challenged subcutaneously with
danaparoid after negative intracutaneous and patch testing
for this substance and developed DTHR against danaparoid
3 days later. In the fourth female, we did not inject danaparoid
subcutaneously.
In the last years, the synthetic pentasaccharide fondapar-
inux sodium has become available as an alternative antico-
agulant, a drug with only rarely reported cross-reactivity with
heparins that may also be applied during pregnancy.12Y16 In our
study, 14 of 15 patients had a subcutaneous challenge with
fondaparinux. Pregnant women as well as all other tested
patients tolerated application of fondaparinux well without
local or systemic side effects. We therefore recommend fonda-
parinux and danaparoid as alternative drugs in pregnant female
patients with DTHR against LMWH.
In patients with an urgent indication for cardiac surgery,
the selection of an adequate alternative is even more limited
because of several reasons. In most of these cases, extra-
corporeal circulation is needed during the operation. Until now,
heparin sodium is the drug that can be controlled best during
such an intervention because it has a short half-life and it can be
antagonized by protamine sulfate.17
Lepirudin is a potential alternative drug, but this drug
has a long half-life, and the risk of bleeding is high because
there is no antidote for this substance.17 Furthermore, this drug
may cause severe anaphylactic reactions, primarily in patients
with repeated exposure to lepirudin and also in patients without
previous contact.18Y20 It is remarkable that 2 of our patients
developed DTHR after subcutaneous lepirudin administration,
which is only rarely seen. One of these patients already had a
positive reaction in intracutaneous testing, whereas the other
one had none.
Bivalirudin, one of the newer synthetic direct thrombin
inhibitors, is also a potential alternative for patients with an
indication for heart surgery. The drug has already been used
Bon-[ and Boff-pump[ in heart surgery in patients with heparin-
induced thrombocytopenia or immunoglobulin EYmediated
heparin allergy.21Y23 The advantages of this drug are its short
half-life of about 25 minutes, and its predominant nonorgan
elimination by proteolysis.22 Furthermore, in contrast to hi-
rudin, bivalirudin only binds transiently to the thrombin mol-
ecule. Bivalirudin has a low antigenic potential because it
represents a small polypeptide; however, it shares a sequence
of 11 amino acids with lepirudin.23 Eichler and coworkers,23
who investigated sera from 43 patients with antibodies against
lepirudin could show that more than 50% of these sera were
also reactive with bivalirudin. Therefore, one should be cautious
of using bivalirudin in patients pretreated with lepirudin. In
patients with a history of anaphylaxis after lepirudin exposure,
bivalirudin should be avoided.
Argatroban is another synthetic thrombin inhibitor that
inhibits free as well as ﬁbrin- and clot-bound thrombin.24 The-
oretically, this drug is also an alternative in patients with heparin
allergy and in need of cardiac surgery. Up to now, there is only
limited experience with this drug in cardiac surgery.25 Similar
to other thrombin inhibitors, there is no antidote available.
However, there are several reports of cardiac surgery per-
formed successfully using argatroban as an anticoagulant.24,26,27
All other drugs that are available as alternatives to UFH
have to be considered as inappropriate at the present stage of
knowledge.
In our patients, we tested neither bivalirudin nor
argatroban because there is limited experience with these
drugs and because heparin is ideal for the setting of cardiac
surgery. In principle, bivalirudin as well as argatroban may be
tested before heart surgery, but this should always depend on
the recommendation of the treating hemostaseologists, anes-
thesiologists, and heart surgeons.
In patients with heart diseases investigated in this case
series, the diagnostic procedure was always discussed inter-
disciplinary before allergologic testing. As in all cases, heparin
sodium seemed to be the drug that can be controlled best under
heart surgery; we performed an intravenous challenge with
heparin sodium as previously described. The intravenous pro-
vocation was well tolerated in all cases. This observation is
consistent with the results of Gaigl and coworkers28 who per-
formed intravenous heparin sodium provocation in 28 patients
with a history of DTHR against subcutaneously injected
heparin sodium. In their cohort, this challenge was well tol-
erated in all cases. The reason for intravenous tolerance despite
development of DTHR after administration of the same drug
subcutaneously is probably a phenomenon called compartment
allergy based on a difference in antigen processing and
presentation and preferential homing of selectively sensitized
lymphocytes in the dermis.3 Anyhow, hematogenous DTHR
such as the development of the baboon syndrome cannot be
excluded, but seems to be negligible in patients with an urgent
indication of heart surgery. In emergency cases, intravenous
application of heparin sodium may be performed even
without prior allergologic testing, although development of
maculopapular exanthemas or ﬂare-ups cannot be excluded.9
We also prefer intravenous provocation of heparin sodium in
patients in need of cardiac surgery instead of using lepirudin,
bivalirudin, or argatroban.28
Until now, it is still unclear if patients with a history of
DTHR have an increased risk of developing systemic com-
plications such as thrombosis, skin necrosis, or HIT type II
after reexposure to heparin. Harenberg and coworkers29
investigated 9 patients with cutaneous heparin-induced allergic
reactions after subcutaneous heparin application. Three (33.4%)
of 9 patients showed pathological heparin-induced platelet
activation (HIPA). Two of 3 HIPA-positive patients showed
elevated heparin-induced immunoglobulin G titers and devel-
oped skin necrosis or heparin-induced thrombosis upon heparin
administration, without decrease of platelet count. Aside from
the report of Harenberg et al,29 there is not much evidence for a
coincidence of DTHR after subcutaneous heparin administra-
tion and the development of systemic complications or the
production of heparin antibodies. Larger trials including
Pfo¨hler et al WAO Journal & December 2008
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allergologic testing as previously described and extensive
laboratory investigation such as evaluation of heparin antibodies
or HIPA are still missing. Under this aspect, potential systemic
complications must be accepted, at least in patients with an
urgent indication of cardiac surgery.
As allergic reactions after heparin administration may
belong to different types of allergic reactions according to the
Coombs and Gell classiﬁcation, we recommend the following
test procedures in patients with a history of heparin allergy:
intracutaneous testing of UFH, LMWH, heparinoids, hirudins,
and fondaparinux as previously described. Prick testing is not
necessary in patients with DTHR and should only be per-
formed in special situations, for example, in patients with a
history of type I reactions after heparin administration. Patch
testing can be omitted because of reduced sensitivity. Intra-
cutaneous testing should be followed by subcutaneous chal-
lenge with drugs that had been negative in intracutaneous and
patch testing. The repertory of drugs tested must be reduced in
pregnant women and patients with an indication of cardiac
surgery according to contraindications of several drugs in
pregnancy and the actual recommendation of the responsible
hemostaseologists, anesthesiologists, or heart surgeons. Up to
now, there is no indication to test bivalirudin or argatroban
routinely in patients with DTHR after heparin exposure. Bi-
opsies from allergic skin reaction may help identify type II or
III reactions.
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